Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) from a sell rating to a hold rating in a research note published on Friday morning.

Other research analysts have also recently issued reports about the company. Craig Hallum started coverage on Delcath Systems in a research report on Friday, June 28th. They set a buy rating and a $18.00 price objective on the stock. HC Wainwright reaffirmed a buy rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday, August 6th. Finally, Stephens reiterated an overweight rating and issued a $25.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Stock Up 3.0 %

Shares of DCTH opened at $9.14 on Friday. The stock has a market cap of $253.96 million, a P/E ratio of -3.45 and a beta of 0.78. The business’s 50 day moving average price is $8.92 and its 200-day moving average price is $7.28. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $11.74.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the previous year, the business posted ($0.58) earnings per share. On average, equities analysts anticipate that Delcath Systems will post -1.67 EPS for the current year.

Institutional Trading of Delcath Systems

Hedge funds have recently modified their holdings of the company. Levin Capital Strategies L.P. raised its holdings in shares of Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after buying an additional 5,969 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Delcath Systems during the second quarter valued at $370,000. Renaissance Technologies LLC acquired a new position in shares of Delcath Systems in the 2nd quarter valued at $694,000. Marshall Wace LLP raised its stake in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Delcath Systems during the 4th quarter worth about $962,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.